SAN DIEGO, March 25, 2024 /PRNewswire/ -- Poseida
Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene
therapy company advancing a new class of treatments for patients
with cancer and rare diseases, today announced the appointment of
Syed Rizvi, M.D., as Chief Medical
Officer effective April 1, 2024. Dr.
Rizvi is a seasoned executive with over 20 years of experience
across all stages of drug development, including clinical strategy,
execution, and commercialization.
"Syed brings to Poseida an impressive combination of industry
leadership and highly specialized drug development experience in
cell therapy, and I am excited to welcome him to our leadership
team during this important period of execution across our clinical
stage CAR-T portfolio," said Kristin
Yarema, Ph.D., President and Chief Executive Officer of
Poseida. "Syed has a proven track record in guiding the development
and commercialization of multiple cancer treatments, including
three approved autologous CAR-T cell therapies, and his
expertise will be an invaluable asset as we usher in the next wave
of cell and gene therapies."
"Poseida's compelling and proprietary science, impressive
manufacturing capabilities, and execution-focused mindset position
the Company to bring potentially transformative therapies to
patients with significant unmet medical need," said Dr. Rizvi.
"I look forward to working with an experienced leadership team to
advance Poseida's promising pipeline of allogeneic CAR-T and gene
therapy programs at an important and exciting time for the
Company."
Dr. Rizvi most recently served as Chief Medical Officer of
Caribou Biosciences, where he was responsible for overall strategy
and execution of all clinical development programs. Prior to
joining Caribou, he served as Chief Medical Officer at Chimeric
Therapeutics, where he helped build the company's pipeline by
licensing programs from leading universities and progressing
existing programs through the clinical development process. Dr.
Rizvi previously led the development of CARVYKTI®, an
approved autologous BCMA CAR-T cell therapy for myeloma, along with
other therapies as part of the leadership team at Legend Biotech.
Prior to that, he was the global medical head of the CAR-T
program at Celgene, where he was responsible for the global medical
strategy for both ABECMA® in myeloma and
BREYANZI® in lymphoma, supporting the clinical
development strategy resulting in approval and potential label
expansion into additional indications. Dr. Rizvi previously held
global clinical leadership roles of increasing responsibility at
Novartis, Merck, and Genta, Inc.
Dr. Rizvi received his medical degree from Dow Medical
College and spent several years as a physician specializing in
hematology and oncology before moving into a clinical research role
at St. Vincent's Comprehensive Cancer Center in New York. He has authored multiple scientific
publications in peer-reviewed journals and is a member of the
American Society of Clinical Oncology, the American Society of
Hematology, the American Society for Transplantation and Cellular
Therapy, and the European Hematology Association, among other
professional organizations.
About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical
company advancing differentiated cell and gene therapies with the
capacity to cure certain cancers and rare diseases. The Company's
pipeline includes allogeneic CAR-T cell therapy product candidates
for both solid and liquid tumors as well as in vivo gene therapy
product candidates that address patient populations with high unmet
medical need. The Company's approach to cell and gene therapies is
based on its proprietary genetic editing platforms, including its
non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific
Gene Editing System, Booster Molecule, and nanoparticle and hybrid
gene delivery technologies as well as in-house GMP cell therapy
manufacturing. The Company has formed a global strategic
collaboration with Roche to unlock the promise of cell therapies
for patients with hematological malignancies. Learn more at
www.poseida.com and connect with Poseida on X and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include statements
regarding, among other things, expected plans with respect to
clinical trials, including timing of regulatory submissions and
approvals and clinical data updates; anticipated timelines
and milestones with respect to the Company's development programs
and manufacturing activities and capabilities; the potential
capabilities and benefits of the Company's technology platforms and
product candidates; the quotes from Dr. Yarema and Dr. Rizvi;
future contributions of the Company's executive officers; the
timing of the expected start date of Dr. Rizvi; the Company's
ability to exploit and consummate additional business development
opportunities; and the Company's plans and strategy with respect to
developing its technologies and product candidates. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. These forward-looking statements are
based upon the Company's current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results could differ materially from those
anticipated in such forward-looking statements as a result of
various risks and uncertainties, which include, without limitation,
the Company's reliance on third parties for various aspects of its
business; risks and uncertainties associated with development and
regulatory approval of novel product candidates in the
biopharmaceutical industry; the Company's ability to retain key
scientific or management personnel; and the other risks described
in the Company's filings with the Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. The
Company undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made, except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-appoints-syed-rizvi-md-as-chief-medical-officer-302098580.html
SOURCE Poseida Therapeutics, Inc.
